Suzhou Zelgen Biopharmaceuticals Co Ltd (688266) - Total Liabilities

Latest as of September 2025: CN¥1.86 Billion CNY ≈ $272.82 Million USD

Based on the latest financial reports, Suzhou Zelgen Biopharmaceuticals Co Ltd (688266) has total liabilities worth CN¥1.86 Billion CNY (≈ $272.82 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore Suzhou Zelgen Biopharmaceuticals Co Ltd equity growth rate to track the company's year-over-year net asset growth rate.

Suzhou Zelgen Biopharmaceuticals Co Ltd - Total Liabilities Trend (2016–2024)

This chart illustrates how Suzhou Zelgen Biopharmaceuticals Co Ltd's total liabilities have evolved over time, based on quarterly financial data. See how much free cash does Suzhou Zelgen Biopharmaceuticals Co Ltd generate to measure how efficiently the company converts operating cash flow to free cash.

Suzhou Zelgen Biopharmaceuticals Co Ltd Competitors by Total Liabilities

The table below lists competitors of Suzhou Zelgen Biopharmaceuticals Co Ltd ranked by their total liabilities.

Company	Country	Total Liabilities
Jinneng Holding Shanxi Coal Industry Co Ltd SHG:601001	China	CN¥7.96 Billion
Alaska Air Group Inc NYSE:ALK	USA	$16.57 Billion
Seaboard Corporation NYSE MKT:SEB	USA	$3.07 Billion
SLM Corp NASDAQ:SLM	USA	$26.97 Billion
Geovis Technology Co Ltd SHG:688568	China	CN¥3.79 Billion
Ningbo Joyson Electronic Corp SHG:600699	China	CN¥45.99 Billion
SentinelOne Inc NYSE:S	USA	$1.00 Billion
Texas Capital Bancshares, Inc. NASDAQ:TCBI	USA	$29.88 Billion

Liability Composition Analysis (2016–2024)

This chart breaks down Suzhou Zelgen Biopharmaceuticals Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see 688266 market cap overview.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	1.85	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	1.62	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.62	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Suzhou Zelgen Biopharmaceuticals Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Suzhou Zelgen Biopharmaceuticals Co Ltd (2016–2024)

The table below shows the annual total liabilities of Suzhou Zelgen Biopharmaceuticals Co Ltd from 2016 to 2024.

Year	Total Liabilities	Change
2024-12-31	CN¥1.75 Billion ≈ $256.37 Million	+41.02%
2023-12-31	CN¥1.24 Billion ≈ $181.80 Million	+41.05%
2022-12-31	CN¥880.82 Million ≈ $128.89 Million	+78.71%
2021-12-31	CN¥492.88 Million ≈ $72.12 Million	+76.85%
2020-12-31	CN¥278.69 Million ≈ $40.78 Million	+13.05%
2019-12-31	CN¥246.52 Million ≈ $36.07 Million	+42.30%
2018-12-31	CN¥173.24 Million ≈ $25.35 Million	+132.21%
2017-12-31	CN¥74.61 Million ≈ $10.92 Million	+168.71%
2016-12-31	CN¥27.76 Million ≈ $4.06 Million	--

About Suzhou Zelgen Biopharmaceuticals Co Ltd

SHG:688266 China Biotechnology

Market Cap

$4.35 Billion

CN¥29.71 Billion CNY

Market Cap Rank

#3914 Global

#571 in China

Share Price

CN¥112.22

Change (1 day)

+1.69%

52-Week Range

CN¥75.75 - CN¥147.40

All Time High

CN¥147.40